G Rodari1,2, A Cattoni3,4, A Albanese3. 1. Paediatric Unit, Royal Marsden NHS Foundation Trust, Sutton, UK. rodarigiulia@gmail.com. 2. Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, University of Milan, Via Francesco Sforza 28, 20122, Milan, Italy. rodarigiulia@gmail.com. 3. Paediatric Unit, Royal Marsden NHS Foundation Trust, Sutton, UK. 4. Paediatric Department, Azienda Ospedaliera San Gerardo, Fondazione Monza e Brianza per il Bambino e la sua Mamma, Monza, Italy.
Abstract
PURPOSE: Growth hormone deficiency (GHD) is the most prevalent hypothalamic-pituitary (HP) disorder found in childhood cancer survivors (CCS). The published studies assessing GHD in CCS concluded that recombinant human GH (rhGH) does not restore final height (FH) to that predicted from mid-parental height (MPH). Thus, wider analyses on final height outcomes after rhGH in CCS are needed. METHODS: Retrospective study on final height (FH) in 87 CCS treated with rhGH. Patients were divided into: Group A (n =48) who underwent cranial radiotherapy or had non-irradiated tumours of HP area, and B (n =39) who were treated with craniospinal or total body irradiation (TBI). 19/87 patients with central precocious/early puberty also received GnRH analogues. RESULTS: Height (HT) gain after 1 and 2 years of rhGH was 0.38 ± 0.35 SDS and 0.18 ± 0.30 SDS, respectively (P < 0.0001); mean FH was in the normal range (- 0.85 ± 1.34 SDS), though not significantly different from HT SDS at baseline. 67% overall failed to reach MPH especially in Group B (P < 0.0001). However, height loss (HT SDS-MPH SDS) at FH improved or remained stable compared to baseline in 26/45 patients (58%). On stepwise regression analysis, major determinants of FH were HT at baseline (P < 0.0001) and delay before start of rhGH (P = 0.012). There was no significant difference in FH when GnRHa was added to rhGH. CONCLUSION: rhGH and GnRH analogues therapy, when indicated, though failing to induce catch-up growth, prevented further height loss leading to a FH within the normal range but still below MPH, this latter being statistically significant in children who received craniospinal and TBI.
PURPOSE:Growth hormone deficiency (GHD) is the most prevalent hypothalamic-pituitary (HP) disorder found in childhood cancer survivors (CCS). The published studies assessing GHD in CCS concluded that recombinant human GH (rhGH) does not restore final height (FH) to that predicted from mid-parental height (MPH). Thus, wider analyses on final height outcomes after rhGH in CCS are needed. METHODS: Retrospective study on final height (FH) in 87 CCS treated with rhGH. Patients were divided into: Group A (n =48) who underwent cranial radiotherapy or had non-irradiated tumours of HP area, and B (n =39) who were treated with craniospinal or total body irradiation (TBI). 19/87 patients with central precocious/early puberty also received GnRH analogues. RESULTS: Height (HT) gain after 1 and 2 years of rhGH was 0.38 ± 0.35 SDS and 0.18 ± 0.30 SDS, respectively (P < 0.0001); mean FH was in the normal range (- 0.85 ± 1.34 SDS), though not significantly different from HT SDS at baseline. 67% overall failed to reach MPH especially in Group B (P < 0.0001). However, height loss (HT SDS-MPH SDS) at FH improved or remained stable compared to baseline in 26/45 patients (58%). On stepwise regression analysis, major determinants of FH were HT at baseline (P < 0.0001) and delay before start of rhGH (P = 0.012). There was no significant difference in FH when GnRHa was added to rhGH. CONCLUSION:rhGH and GnRH analogues therapy, when indicated, though failing to induce catch-up growth, prevented further height loss leading to a FH within the normal range but still below MPH, this latter being statistically significant in children who received craniospinal and TBI.
Entities:
Keywords:
Cancer survivors; Final height; GnRH analogues; Growth hormone
Authors: P Bang; R Bjerknes; J Dahlgren; L Dunkel; J Gustafsson; A Juul; B Kriström; P Tapanainen; V Aberg Journal: Horm Res Paediatr Date: 2011-01-12 Impact factor: 2.852
Authors: Wassim Chemaitilly; Thomas E Merchant; Zhenghong Li; Nicole Barnes; Gregory T Armstrong; Kirsten K Ness; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Melissa M Hudson; Charles A Sklar; Amar Gajjar Journal: Clin Endocrinol (Oxf) Date: 2015-11-16 Impact factor: 3.478
Authors: M Ciaccio; S Gil; G Guercio; E Vaiani; D Alderete; M Palladino; D M Warman; M A Rivarola; A Belgorosky Journal: Horm Res Paediatr Date: 2010-03-09 Impact factor: 2.852
Authors: Charles A Sklar; Zoltan Antal; Wassim Chemaitilly; Laurie E Cohen; Cecilia Follin; Lillian R Meacham; M Hassan Murad Journal: J Clin Endocrinol Metab Date: 2018-08-01 Impact factor: 5.958
Authors: D Beckers; M Thomas; J Jamart; I Francois; M Maes; M C Lebrethon; K De Waele; S Tenoutasse; J De Schepper Journal: Eur J Endocrinol Date: 2009-12-07 Impact factor: 6.664
Authors: O O Golounina; M G Pavlova; Z E Belaya; E I Kim; I V Glinkina; T B Morgunova; N A Mazerkina; O G Zheludkova; V V Fadeev Journal: Probl Endokrinol (Mosk) Date: 2021-01-08
Authors: Julia Anttonen; Tiina Remes; Pekka Arikoski; Päivi Lähteenmäki; Mikko Arola; Arja Harila-Saari; Tuula Lönnqvist; Tytti Pokka; Pekka Riikonen; Kirsti Sirkiä; Heikki Rantala; Marja Ojaniemi Journal: PLoS One Date: 2022-09-06 Impact factor: 3.752